10617 studies found for:    NCI
Show Display Options
RSS Create an RSS feed from your search for:
NCI
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: recombinant fowlpox-prostate specific antigen vaccine;   Biological: recombinant vaccinia prostate-specific antigen vaccine;   Biological: recombinant vaccinia-B7.1 vaccine;   Biological: sargramostim;   Drug: docetaxel
2 Active, not recruiting Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Condition: Neuroendocrine Carcinoma
Interventions: Biological: Recombinant Interferon Alfa-2b;   Drug: Octreotide Acetate;   Biological: Bevacizumab
3 Completed
Has Results
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus
Conditions: Barrett Esophagus;   Esophageal Cancer
Interventions: Drug: metformin hydrochloride;   Other: placebo
4 Active, not recruiting
Has Results
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Adult Anaplastic Oligodendroglioma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Unknown  Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Biological: cetuximab;   Other: placebo;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
6 Terminated
Has Results
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: Akt inhibitor MK2206;   Drug: selumetinib;   Other: laboratory biomarker analysis
7 Completed Caspofungin Acetate in Treating Children With Fever and Neutropenia
Conditions: Fever, Sweats, and Hot Flashes;   Infection;   Kidney Cancer;   Leukemia;   Lymphoma;   Neuroblastoma;   Neutropenia;   Sarcoma
Intervention: Drug: caspofungin acetate
8 Completed Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Splenic Marginal Zone Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: alvocidib;   Drug: fludarabine phosphate;   Biological: rituximab;   Other: pharmacological study
9 Terminated FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis
10 Completed
Has Results
Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
Conditions: Precancerous Condition;   Stage I Non-small Cell Lung Cancer;   Tobacco Use Disorder
Interventions: Drug: sulindac;   Other: placebo
11 Completed Monoclonal Antibody Therapy in Treating Patients With Leukemia
Conditions: Lymphoma;   Radiation Toxicity
Interventions: Drug: pentetic acid calcium;   Radiation: yttrium Y 90 daclizumab
12 Completed Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
Condition: Recurrent Small Cell Lung Cancer
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis
13 Completed Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: irinotecan hydrochloride;   Drug: thalidomide;   Other: pharmacological study
14 Completed Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers
Condition: No Evidence of Disease
Interventions: Drug: Celecoxib;   Other: Laboratory Biomarker Analysis;   Procedure: UV Light Therapy
15 Recruiting Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Vorinostat
16 Completed
Has Results
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx
Intervention: Drug: Akt inhibitor MK2206
17 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Gamma-Secretase Inhibitor RO4929097;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Procedure: Therapeutic Conventional Surgery
18 Not yet recruiting Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia
Interventions: Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
19 Completed Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: placebo;   Drug: Bowman-Birk inhibitor concentrate
20 Recruiting Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years